Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer.
Juan Jose Perez RuixoOliver AckaertDaniele OuelletCaly ChienHiroji UemuraDavid OlmosPaul MainwaringJi Youl LeeMargaret K YuMatthew R SmithEric J SmallPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The use of apalutamide at the recommended dose of 240 mg once daily provided a similar delay in metastases across the SPARTAN patient population, regardless of exposure. The exploratory exposure-safety analysis supports dose reductions in patients experiencing adverse events.